Comparative Pharmacology
Head-to-head clinical analysis: BREVICON 21 DAY versus MICROGESTIN FE 1 5 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREVICON 21 DAY versus MICROGESTIN FE 1 5 30.
BREVICON 21-DAY vs MICROGESTIN FE 1.5/30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin (FSH, LH) release via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation. Increases viscosity of cervical mucus and alters endometrial lining to impede sperm penetration and implantation.
Combination oral contraceptive: ethinyl estradiol (estrogen) and norethindrone acetate (progestin) suppress gonadotropin (FSH, LH) release, preventing ovulation; increase cervical mucus viscosity, inhibiting sperm penetration; alter endometrial development, reducing implantation likelihood.
One tablet (0.5 mg norethindrone and 0.035 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days off.
One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily for 28-day cycles (21 active tablets + 7 ferrous fumarate tablets).
None Documented
None Documented
Norethindrone: 7-8 hours; Ethinyl estradiol: 13-17 hours. Clinical context: Steady state reached within 5-7 days; missed pills may reduce contraceptive efficacy.
Norethindrone: 6-8 hours (terminal); Ethinyl estradiol: 12-18 hours (terminal). Clinical context: Steady-state achieved within 5-7 days; dosing interval suitable for once-daily administration.
Urine (50-60% as metabolites, <10% unchanged); feces (30-40% as metabolites); biliary (minor).
Norethindrone: 50-60% renal (as metabolites), 20-40% fecal; Ethinyl estradiol: ~40% renal, ~60% fecal (as glucuronide/sulfate conjugates).
Category C
Category C
Oral Contraceptive
Oral Contraceptive